Hugin Ad hoc announcement according to § 15 WpHG: Misc. business figure: STRATEC Biomedical Systems AG: STRATEC raises sales and earnings forecast for 2006 and 2007 significantly

Birkenfeld, September 7, 2006

STRATEC Biomedical Systems AG (Prime Standard and Gate-M, ISIN:
DE0007289001) has significantly increased its sales and earnings
forecast for 2006 and 2007.

As a result of the pleasing situation in terms of production orders
and in the development of analyzer systems, the company assumes that
it will be possible to increase its sales for the 2006 financial year
to between Euro 65 million and Euro 68 million (sales corridor).
Improvements in the product portfolio, benefits of scale and
digression effects mean that earnings before tax (EBT) will show
disproportionate growth compared with sales and will reach between
Euro 10.5 million and Euro 11 million (earnings corridor).

Based on current plans, there will be a further significant increase
in the number of analyzer systems produced and delivered in the 2007
financial year. In view of this, the company expects to expand its
sales in the 2007 financial year to between Euro 75 million and
Euro 78 million (sales corridor) and to be able to achieve earnings
before tax (EBT) of between Euro 14 million and Euro 15 million
(earnings corridor).

This ad-hoc announcement (statutory company announcement) contains
forward-looking statements based on current assumptions and forecasts
made by the management of the STRATEC Group. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given
here.


Information and explanatory remarks concerning this ad-hoc
announcement:

This sales and earnings forecast has been compiled exclusively on the
basis of the serial analyzer systems actually in development and/or
production.

The new budget figures are considerably higher than the internal
budget targets most recently forecast in December 2005. These
forecast that the sales for the 2006 financial year would increase to
Euro 55 million to Euro 59 million (sales corridor) and that earnings
before tax (EBT) would rise to Euro 8.3 million to Euro 9.2 million
(earnings corridor). An average annual growth rate (CAGR) of more
than 15% in the case of sales and of more than 22% for earnings
before tax (EBT) was forecast for the subsequent 2007 to 2009
financial years.

The company is publishing a long-term sales and earnings forecast
going beyond the 2007 financial year in a press release to be issued
separately today.


About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)
designs and manufactures fully automated systems for its partners in
the fields of clinical diagnostics and biotechnology. These partners
market such systems, in general together with their own reagents, to
laboratories and research institutes around the world. The company
develops its products on the basis of its own patented technologies.
Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded
in the Prime Standard segment of the Frankfurt Stock Exchange, in the
Gate-M trading segment of the Stuttgart Stock Exchange and on other
exchanges.

The STRATEC Group comprises the listed holding company "STRATEC
Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",
"Robion" and "Sanguin".


Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
E-Mail: ir@stratec-biomedical.de



--- End of Ad-hoc Message ---
WKN: 728900; ISIN: DE0007289001;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in
Börse Stuttgart,
Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse
München,
Freiverkehr in Börse Düsseldorf;